ArticlemAbs
Process intensification in fed-batch production bioreactors using non-perfusion seed cultures.
Article in mAbs. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Impact of N-1 phase media optimization as a bioprocess intensification strategy on fed-batch production.Bioprocess and biosystems engineering · 2026Article
- Developing affordable monoclonal antibodies for LMICs through high performance manufacturing processes and LMIC based commercial manufacturing.Frontiers in pediatrics · 2026Article
- Bioprocess Engineering for Cultivated Meat.Advances in biochemical engineering/biotechnology · 2026Review
- Scale-Up Strategy Focused on Hydrodynamic Stress for Mammalian Cell Culture Established by a Dry-Wet Approach.Engineering in life sciences · 2025Article
- Biotechnology Approaches to Dairy Alternatives Through Precision Fermentation and Cellular Agriculture.Food science of animal resources · 2025Review
- Establishment of a high-throughput scale-down clone screening platform for intensified fed-batch culture of CHO cells.Biotechnology letters · 2025Article
- Enhancing monoclonal antibody production efficiency using CHO-MK cells and specific media in a conventional fed-batch culture.Cytotechnology · 2025Article
- Exploring metabolic effects of dipeptide feed media on CHO cell cultures by in silico model-guided flux analysis.Applied microbiology and biotechnology · 2024Article
- Impact of fed-batch process intensification on the productivity and product quality of two CHO cell lines expressing unique novel molecular format proteins.Bioprocess and biosystems engineering · 2024Article
- Triple Space-Time Yield in Discontinuous Antibody Biomanufacturing by Combination of Synergetic Process Intensification Strategies.Bioengineering (Basel, Switzerland) · 2023Article
- A novel hybrid bioprocess strategy addressing key challenges of advanced biomanufacturing.Frontiers in bioengineering and biotechnology · 2023Article
- Improved Titer in Late-Stage Mammalian Cell Culture Manufacturing by Re-Cloning.Bioengineering (Basel, Switzerland) · 2022Article
- N-1 Perfusion Platform Development Using a Capacitance Probe for Biomanufacturing.Bioengineering (Basel, Switzerland) · 2022Article
- Bioengineering Outlook on Cultivated Meat Production.Micromachines · 2022Review
- Exploring the limits of conventional small-scale CHO fed-batch for accelerated on demand monoclonal antibody production.Bioprocess and biosystems engineering · 2022Article
- Mapping the molecular basis for growth related phenotypes in industrial producer CHO cell lines using differential proteomic analysis.BMC biotechnology · 2021Article
- Article
- Machine learning-assisted clone selection for intensified cell culture processes.Biotechnology progressArticle
- Enhancing CHO cell recombinant protein production using a perfusion-directed host evolution approach.Biotechnology progressArticle
- N-1 semi-continuous transient perfusion in shake flask for ultra-high density seeding of CHO cell cultures in benchtop bioreactors.Biotechnology progressArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although process intensification by continuous operation has been successfully applied in the chemical industry, the biopharmaceutical industry primarily uses fed-batch, rather than continuous or perfusion methods, to produce stable monoclonal antibodies (mAbs) from Chinese hamster ovary (CHO) cells. Conventional fed-batch bioreactors may start with an inoculation viable cell density (VCD) of ~0.5 × 10
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.